Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

Texas MPN Workshop 2022 | An insight into ongoing trials in CMML

Eric Padron • 26 Aug 2022
Texas MPN Workshop 2022
Chronic Myelomonocytic Leukemia Leukemia Myeloproliferative Neoplasms Rare Diseases Ruxolitinib

Eric Padron, MD, H. Lee Moffitt Cancer Center, Tampa, FL, briefly discusses some ongoing trials evaluating therapeutic approaches in chronic myelomonocytic leukemia (CMML). This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.

Disclosures

Research Funding: Kura, Incyte, BMS
Honoraria: Blueprint, Novartis, Stem line, Taiho, Pharmaessentia

More from Eric Padron

Unanswered questions in CMML: timing of treatment initiation to delay progression 0:59
Unanswered questions in CMML: timing of treatment initiation to delay progression
Eric Padron • 22 Aug 2025
The unique challenges that underlie the lack of therapeutic advances in CMML to date 1:36
The unique challenges that underlie the lack of therapeutic advances in CMML to date
Eric Padron • 22 Aug 2025
Using molecular profiling and genomic insights to improve the management of CMML 1:18
Using molecular profiling and genomic insights to improve the management of CMML
Eric Padron • 22 Aug 2025
Updates in the field of CMML: changes in diagnostic criteria & the growing number of clinical trials 1:31
Updates in the field of CMML: changes in diagnostic criteria & the growing number of clinical trials
Eric Padron • 22 Aug 2025

Related Videos

MRD-guided treatment with ibrutinib and venetoclax in previously untreated CLL: analyses of FLAIR 7:15
MRD-guided treatment with ibrutinib and venetoclax in previously untreated CLL: analyses of FLAIR
Talha Munir • 16 Dec 2025
Real-world outcomes of olutasidenib in IDH1-mutated AML previously treated with venetoclax 2:14
Real-world outcomes of olutasidenib in IDH1-mutated AML previously treated with venetoclax
Jorge Cortes • 7 Dec 2025
Patient-reported outcomes from ASC4FIRST study of asciminib in newly diagnosed CML 2:22
Patient-reported outcomes from ASC4FIRST study of asciminib in newly diagnosed CML
Jorge Cortes • 7 Dec 2025
Preliminary human data and clinical implications of asciminib administration during pregnancy in CML 5:08
Preliminary human data and clinical implications of asciminib administration during pregnancy in CML
Elisabetta Abruzzese • 5 Dec 2025
The content of VJHemOnc is intended for healthcare professionals